Center-Authored Papers

Filters: Author is Devine, Steven M  [Clear All Filters]
Journal Article
Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS et al..  2011.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.. Blood. 118(2):282-8. Abstract
Armand P, Kim HT, Zhang M-J, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM et al..  2012.  Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(2):280-288. Abstract
Ciurea SO, Zhang M-J, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM et al..  2015.  Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia.. Blood. Abstract
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH et al..  2017.  High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.. Neurology. Abstract
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O et al..  2015.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.. JAMA neurology. 72(2):159-69. Abstract
Waller EK, Logan BR, Harris WAC, Devine SM, Porter DL, Mineishi S, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI et al..  2014.  Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP et al..  2017.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(11):1154-1161. Abstract
Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A et al..  2017.  PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.. Blood. Abstract
Wood WA, McGinn MK, Wilson D, Deal AM, Khera N, Shea TC, Devine SM, Appelbaum FR, Horowitz MM, Lee SJ.  2016.  Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(11):2092-2099. Abstract
Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN et al..  2016.  Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.. The Journal of clinical investigation. 126(7):2642-60. Abstract
Bredeson C, Le Rademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X et al..  2013.  Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.. Blood. Abstract
Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM et al..  2013.  Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood. Abstract